leisure time -WSS

leisure time

author：knowledge 2025-09-27 18:30:03 - browse：18

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： New oral drug delivery patch is modeled after octopus tentacles

knowledge

hotspot

WSS

Harvard's David Sinclair gets blowback over aging

Streamlined flu vaccines recommended by FDA advisory panel

The United States is paying nearly triple for new Covid vaccines

CDC picks Alphabet's Verily for wasterwater surveillance contract

Immune cells and nerve overgrowth may explain recurring UTI pain

Nobel honors Karikó and Weissman's enduring partnership

explore

leisure time

explore

How to save PrEP access — and even expand it

Stem cell biologist probes earliest stages of human development

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Stem cell biologist probes earliest stages of human development

23andMe had bad news about my health. I wish a person had delivered it

Why Talkspace is targeting Medicare, a tricky market

Cancer drug shortages should be causing more outrage

Medicare innovation center doesn’t save money, experts say

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Congress extends some pandemic preparedness programs

entertainment

Lack of health data on LGBTQ+ people has serious consequences

Lack of health data on LGBTQ+ people has serious consequences

What we owe ALS patients — and why one company fell short

Medicare drug price negotiation continues, as pharma counteroffers

Harvard's David Sinclair gets blowback over aging

Experts study whether long Covid risk adds up with each reinfection

focus

knowledge

hotspot

focus